SCHEDULE: RA Capital Exits Sutro Biopharma Stake

RA Capital Management and its affiliates have fully divested their beneficial ownership in Sutro Biopharma, Inc., reducing their stake to 0.0%.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an Amendment No. 1 to Schedule 13G.
• The filing indicates that as of June 30, 2025, the Reporting Persons beneficially own 0.0% of Sutro Biopharma, Inc.'s Common Stock.
• This represents a complete divestment of their previously held stake in the company.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor like RA Capital Management indicates a strong negative signal regarding their confidence in Sutro Biopharma's future prospects.

Negatives

• RA Capital Management and its affiliates, a significant institutional investor, have reduced their beneficial ownership in Sutro Biopharma, Inc. to 0.0%.
• This complete divestment by a prominent healthcare-focused investment firm could signal a loss of confidence in the company's future prospects or valuation.

Risks

• Investor confidence in Sutro Biopharma may decline following the complete divestment by RA Capital Management and its affiliates.
• The market may interpret this divestment as a negative signal regarding Sutro Biopharma's strategic direction or future performance, potentially impacting share price.

Future Outlook

Not applicable as this filing primarily reports a change in beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.

Industry Context

RA Capital Management is a prominent investment firm specializing in the healthcare and life sciences sectors. Their complete divestment from Sutro Biopharma, a biopharmaceutical company, indicates a specific investment decision within the highly dynamic and capital-intensive biopharma industry. Such moves by significant institutional investors can influence market perception and investor sentiment within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders of Sutro Biopharma, Inc. may experience a negative impact on share price due to the perceived loss of investor confidence following the complete divestment by RA Capital Management and its affiliates.

Key Dates

Recommendation

The complete divestment by a major, specialized institutional investor like RA Capital Management, reducing their stake to 0.0%, sends a strong negative signal about their outlook on Sutro Biopharma. This action suggests a significant lack of confidence in the company's future performance or valuation, warranting a 'sell' recommendation for investors.

Keywords

Sutro Biopharma, RA Capital Management, Schedule 13G, beneficial ownership, divestment, common stock, biopharma, investment firm